Using a virus that grows in black-eyed pea plants, researchers developed a new therapy that could keep metastatic cancers from spreading to the lungs, as well as treat established tumors in the lungs.
New Brunswick, N.J., August 24 2021 – Cancer is a disease that can impact anyone, but it does not impact everyone equally. According to the American Cancer Society, breast cancer is the most commonly diagnosed cancer among Black women, and Black women…
UC San Diego studies using human cell lines and tumors grown in mice provide early evidence that inhibiting RNA-binding proteins, a previously overlooked family of molecules, might provide a new approach for treating some cancers.
Researchers at the University of California, San Francisco, have discovered that aggressive, triple-negative breast cancers (TNBCs) can evade treatment by reorganizing and softening the collagen matrix that surrounds the cancer cells. The study, which will be published April 2 in the Journal of Experimental Medicine (JEM), shows that the softer matrix activates a signaling pathway that promotes the cancer cells’ survival, and suggests that targeting this pathway could enhance the effectiveness of chemo- and radiotherapy in TNBC patients.
New findings, reported in Nature Communications, describe the discovery of a unique dependence of cancer cells on a particular protein, which could lead to desperately needed treatment for hard-to-treat cancers.
The physicians focused on how Black women dealt with getting screened and unique issues relevant to them. They revealed their findings recently in the Journal of Breast Imaging in “Breast Cancer Screening Recommendations: African American Women Are at a Disadvantage.”
Rutgers Cancer Institute expert highlights triple negative breast cancer (TNBC), and aggressive subtype of breast cancer with a high prevalence among younger African American women and those of African descent.
Taking advantage of a cancer cell’s altered metabolism that drives its runaway growth, Princess Margaret researchers are zeroing in on these molecular changes to help them develop more precise drug targets for one of the most deadly breast cancers.
Today, scientists report a new immunotherapy that extends the survival of mice that have triple negative breast tumors, a difficult-to-treat form of cancer. The researchers will present their results at the American Chemical Society Fall 2020 Virtual Meeting & Expo.
Genetic modifier HDAC6 was found to control tumor growth and halt metastasis in triple-negative breast cancer in vivo, according to a new study published in the journal Cancer Research by investigators at the GW Cancer Center.
Researchers examined racial and ethnic differences in genetic testing frequency and results among diverse breast cancer patients diagnosed at age 50 or younger from January 2007 to December 2017. They found that among 1,503 diverse young breast cancer patients, less than half (46.2 percent) completed hereditary breast and ovarian cancer genetic testing. However, the percentage of women who completed genetic testing increased over time from 15.3 percent in 2007 to a peak of 72.8 percent in 2015.
Mount Sinai researchers have designed an innovative experimental therapy that may be able to stop the growth of triple-negative breast cancer, the deadliest type of breast cancer, which has few effective treatment options, according to a study published in Nature Chemical Biology in December.
Women with an aggressive, less-common type of breast cancer, known as triple-negative, versus a more common form of the disease, could be differentiated from each other by a panel of 17 small RNA molecules that are directly influenced by genetic alterations typically found in cancer cells.